This HND piece looks AGAIN at problems with diabetes drugs. But, don't blame me for having repetitive themes. Blame Big Pharma and the FDA for developing and approving these drugs.
The latest class of diabetes drugs to cause concern are the sodium-glucose co-transporter-2 (SGLT-2) inhibitors. They lower blood sugar by blocking reabsorption of glucose by the kidneys, and increase its urinary excretion.
On May 15, 2015, the FDA issued a warning that SGLT-2 inhibitors have caused several cases of diabetic ketoacidosis, which is potentially fatal. All reported patients required emergency room visits or hospitalization to treat the condition. What makes this especially disturbing is that the condition had heretofore only been seen in type 1 diabetics, and it was associated with relatively high blood glucose levels. Not any more.
As if that's not bad enough, the instructions given in the FDA warning are pretty much useless.
Read the complete article.